Qatar has been pioneering precision health in the region for close to a decade. This field enables clinicians to tailor genetic-guided dosing therapies based on the patient’s DNA significantly improving treatment outcomes. To address this gap, Qatar Biobank has collected biodata from around 40,000 participants, which is then sequenced by the Qatar Genome Programme.